ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Mechanistically, the combination MAKV-8-imatinib reduced BCR-ABL expression and phosphorylation, as well as the expression of downstream targets playing a critical role in CML proliferation and survival.